Novartis Ag (NVS) Gains from Sales and Divestitures (2009 - 2015)

Novartis Ag has reported Gains from Sales and Divestitures for 7 years, with the latest figure at $159.0 in Q4 2015.

• Quarterly Gains from Sales and Divestitures fell 56.56% year-over-year to $159.0 in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $1025.0 (up 38.7% YoY) and the FY2014 annual result came in at $739.0, up 56.57% from the prior year.
• Gains from Sales and Divestitures slipped to $159.0 in Q4 2015 per NVS's latest filing, from $431.0 in the prior quarter.
• Over five years, Gains from Sales and Divestitures peaked at $696.0 in Q4 2011 and troughed at $25.0 in Q3 2011.
• A 5-year average of $214.9 and a median of $171.5 in 2012 frame the typical range for Gains from Sales and Divestitures.
• The sharpest annual moves came in 2011 and 2012: Gains from Sales and Divestitures jumped 691.67% in 2011, then plunged 91.58% in 2012.
• Over 5 years, Gains from Sales and Divestitures stood at $696.0 in 2011, then slumped by 70.69% to $204.0 in 2012, then fell by 12.25% to $179.0 in 2013, then jumped by 104.47% to $366.0 in 2014, then slumped by 56.56% to $159.0 in 2015.
• According to Business Quant data, Gains from Sales and Divestitures over the past three periods registered $159.0, $431.0, and $151.0 for Q4 2015, Q3 2015, and Q2 2015 respectively.